Acute heart failure following platinum and taxane-based chemotherapy for high grade ovarian cancer

Acute heart failure following platinum and taxane-based chemotherapy for high grade ovarian cancer

Detalles Bibliográficos
Autores principales:	Danielle S. Lewis, Jerry John, Shannon D. Armbruster
Formato:	Artículo
Lenguaje:	English
Publicado:	Elsevier 2025-02-01
Colección:	Gynecologic Oncology Reports
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2352578925000141

Ejemplares similares

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Yixin Liu, et al.
Publicado: (2019-10-01)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Alex Molassiotis, et al.
Publicado: (2019-06-01)

Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy
por: Hiroaki Nagano, et al.
Publicado: (2016-03-01)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Vijay M Patil, et al.
Publicado: (2014-01-01)

Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers
por: Tibor A. Zwimpfer, et al.
Publicado: (2024-01-01)

Platinum drugs and taxanes: can we overcome resistance?
por: Elena V. Sazonova, et al.
Publicado: (2021-06-01)

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
por: Markowska Janina, et al.
Publicado: (2008-01-01)

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
por: Felisiak-Golabek Anna, et al.
Publicado: (2011-11-01)

Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.
por: Seth A Brodie, et al.
Publicado: (2014-01-01)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Eun Kyo Joung, et al.
Publicado: (2021-01-01)

The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence
por: Chuqing Wu, et al.
Publicado: (2022-11-01)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Shirin Kianersi, et al.
Publicado: (2023-01-01)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Satoshi Imai, et al.
Publicado: (2017-07-01)

Sequential Treatment of Advanced Squamous Lung Cancer:  First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence
por: Jing XU, et al.
Publicado: (2015-05-01)

Cell death in cancer chemotherapy using taxanes
por: Ana P. Xu, et al.
Publicado: (2024-01-01)

Beau’s Lines Resulting from Taxane Chemotherapy
por: Kumpol Aiempanakit
Publicado: (2018-10-01)

Genome-wide study of response to platinum, taxane, and combination therapy in ovarian cancer: in vitro phenotypes, inherited variation, and disease recurrence
por: Brooke L Fridley, et al.
Publicado: (2016-03-01)

Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer
por: Kazuhiro Suzuki, et al.
Publicado: (2024-11-01)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Kaname Uno, et al.
Publicado: (2022-03-01)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
por: Ryutaro Onaga, et al.
Publicado: (2023-06-01)

Platinum-based chemotherapy promotes antigen presenting potential in monocytes of patients with high-grade serous ovarian carcinoma
por: Irina Larionova, et al.
Publicado: (2024-09-01)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Lan G. Coffman, et al.
Publicado: (2022-09-01)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: T M Anoop, et al.
Publicado: (2022-01-01)

RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer
por: Sarah J. Taylor, et al.
Publicado: (2024-04-01)

3468 Predictive biomarkers of platinum-based chemotherapy response in Puerto Rican Hispanics with high-grade serous ovarian cancer.
por: Jeyshka M. Reyes-Gonzalez, et al.
Publicado: (2019-03-01)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Amelia M. Jernigan, et al.
Publicado: (2013-01-01)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Zheng Feng, et al.
Publicado: (2023-03-01)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Jiaxing Lin, et al.
Publicado: (2021-02-01)

Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy studyResearch in context
por: Indra A. Van Assche, et al.
Publicado: (2024-12-01)

The Future of Chemotherapy: The Mechanisms and Benefits of Exercise in Taxane-Induced Peripheral Neuropathy
por: Sumedha Shastry, et al.
Publicado: (2023-11-01)

Chemotherapy Associated Ovarian Failure
por: Davide Mauri, et al.
Publicado: (2020-12-01)

Establishment and Genetic Profiling of Platinum/Taxane Doublet-Resistant Cells Generated by Hybridizing Single Resistant Cells
por: Seiji Isonishi, et al.
Publicado: (2022-09-01)

Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors
por: Robert Knoerl, et al.
Publicado: (2021-09-01)

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
por: İlker Selçuk, et al.
Publicado: (2015-04-01)

Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer
por: Jiao Liu, et al.
Publicado: (2023-11-01)

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
por: Carlos J Diaz Osterman, et al.
Publicado: (2019-09-01)

Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy
por: Chuan-Jen Hung, et al.
Publicado: (2022-10-01)

A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
por: Du Y, et al.
Publicado: (2018-11-01)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Yue Zhao, et al.
Publicado: (2022-09-01)

Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape.
por: Ramya Ganesan, et al.
Publicado: (2023-09-01)